natgillin/translations-raw huggingface dataset:
You may still be able to use Abseamed, but discuss it with your doctor first:
Abseamedi kasutamine ei pruugi olla välistatud, aga sellegipoolest pidage enne nõu oma arstiga, kui
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 1000 RÜ/0,5 ml süstelahus süstlis Abseamed 2000 RÜ/1 ml süstelahus süstlis Abseamed 3000 RÜ/0,3 ml süstelahus süstlis Abseamed 4000 RÜ/0,4 ml süstelahus süstlis Abseamed 5000 RÜ/0,5 ml süstelahus süstlis Abseamed 6000 RÜ/0,6 ml süstelahus süstlis Abseamed 7000 RÜ/0,7 ml süstelahus süstlis Abseamed 8000 RÜ/0,8 ml süstelahus süstlis Abseamed 9000 RÜ/0,9 ml süstelahus süstlis Abseamed 10 000 RÜ/1 ml süstelahus süstlis Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis Abseamed 30 000 RÜ/0,75 ml süstelahus süstlis Abseamed 40 000 RÜ/1 ml süstelahus süstlis
Abseamed should be administered in order to increase haemoglobin to not greater than 11 g/dL (6.8 mmol/L).
Abseamedi manustamise eesmärgiks on saavutada hemoglobiinisisaldus, mis ei ületa 11 g/dl (6,8 mmol/l).
If the haemoglobin level reaches 15 g/dL (9.38 mmol/L), or higher, during the preoperative period, administration of Abseamed should be stopped and further dosages should not be administered.
Kui hemoglobiinisisaldus jõuab preoperatiivse perioodi vereanalüüsides väärtuseni 15 g/dl (9,38 mmol/l) või ületab selle, tuleb ravi Abseamediga katkestada ja järgnevaid annuseid ei tohi manustada.
Do not use Abseamed:
Ärge kasutage Abseamedi:
Caution should be exercised with escalation of Abseamed doses in patients with chronic renal failure.
Ettevaatlik tuleb olla Abseamedi annuste suurendamisel kroonilise neerupuudulikkusega patsientidel.
The recommended starting dose is Abseamed 450 IU/kg (maximum total dose is 40,000 IU) administered subcutaneously once every week, with not less than 5 days between doses.
Abseamedi soovitatav algannus on 450 RÜ/kg (maksimaalne koguannus on 40 000 RÜ), manustatuna subkutaanselt kord nädalas nõnda, et annuste vahele jääb vähemalt viis päeva.
Abseamed is indicated in adults receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e.g. cardiovascular status, pre-existing anaemia at the start of chemotherapy) for the treatment of anaemia and reduction of transfusion requirements.
Abseamed on näidustatud aneemia raviks ja vereülekannete vajaduse vähendamiseks soliidtuumori, maliigse lümfoomi või hulgimüeloomiga täiskasvanutel, kes saavad keemiaravi ja kellel on oma üldseisundi tõttu risk vereülekanneteks (nt kardiovaskulaarne seisund, aneemia olemasolu enne keemiaravi alustamist).
Abseamed is used to treat anaemia in adults with a bone marrow disorder that causes a severe disruption in the creation of blood cells (myelodysplastic syndromes).
Abseamedi kasutatakse aneemia raviks vererakkude moodustamist tugevalt kahjustava luuhäirega (müelodüsplastiline sündroom) täiskasvanutel.
Abseamed contains less than 1 mmol sodium (23 mg) per dose that is to say essentially “sodium free”.
Abseamed sisaldab vähem kui 1 mmol (23 mg) naatriumi annuse kohta, see tähendab põhimõtteliselt „naatriumivaba”.
Abseamed should be administered by the intravenous route.
Abseamedi tuleb manustada intravenoosselt.
• The starting dose is either 150 IU per kilogram body weight three times a week or 450 IU per kilogram body weight once a week.
• Algannuseks on kas 150 RÜ kehakaalu kilogrammi kohta kolm korda nädalas või 450 RÜ
Where intravenous access is not readily available Abseamed may be administered subcutaneously.
Kui puudub intravenoosne manustamistee, võib Abseamedi manustada subkutaanselt.
Abseamed is indicated for the treatment of symptomatic anaemia associated with chronic renal failure (CRF):
Abseamed on näidustatud kroonilise neerupuudulikkusega seotud sümptomaatilise aneemia raviks:
Abseamed is indicated for non-iron deficient adults prior to major elective orthopaedic surgery, having a high perceived risk for transfusion complications to reduce exposure to allogeneic blood transfusions.
Abseamed on näidustatud allogeense vereülekande vajaduse vähendamiseks enne ulatuslikku ortopeedilist lõikust täiskasvanutel, kellel ei esine rauavaegustja on suurenenud risk vereülekannetega seotud tüsistuste tekkeks.
Only one dose of Abseamed from each syringe should be taken.
Igast süstlist võib võtta ainult ühe Abseamedi annuse.
- All contraindications associated with autologous blood predonation programmes should be respected in patients being supplemented with Abseamed.
- Abseamedi kasutavate patsientide puhul tuleb arvestada kõigi autoloogse vere eelneva kogumise programmiga seonduvate vastunäidustustega.
If the haemoglobin exceeds 13 g/dL (8.1 mmol/L), discontinue therapy until it falls below 12 g/dL (7.5 mmol/L) and then reinstitute Abseamed therapy at a dose 25% below the previous dose.
Kui hemoglobiinisisaldus ületab 13 g/dl (8,1 mmol/l), katkestage ravi, kuni hemoglobiinisisaldus langeb alla 12 g/dl (7,5 mmol/l) ja seejärel taasalustage ravi Abseamediga varasemast 25% väiksema annusega.
If the haemoglobin concentration is increasing by more than 2 g/dL (1.25 mmol/L) per month, or if the haemoglobin concentration level exceeds 12 g/dL (7.5 mmol/L), reduce the Abseamed dose by about 25 to 50%.
Kui hemoglobiinisisaldus tõuseb ühe kuu kohta rohkem kui 2 g/dl (1,25 mmol/l) või kui hemoglobiinisisaldus ületab 12 g/dl (7,5 mmol/l), vähendage Abseamedi annust ligikaudu 25 kuni 50%.
In patients with chronic renal failure where intravenous access is routinely available (haemodialysis patients) administration of Abseamed by the intravenous route is preferable.
Kroonilise neerupuudulikkusega patsientidel, kellel on olemas intravenoosne juurdepääs (hemodialüüsitavad patsiendid), on eelistatud Abseamedi intravenoosne manustamine.
• difficulty swallowing or breathing,
• raskusi neelamisel või hingamisel, • sügelevat löövet (kuplasid).
If the haemoglobin is rising by more than 2 g/dL (1.25 mmol/L) per month, or if the sustained haemoglobin exceeds 12 g/dL (7.5 mmol/L) reduce the Abseamed dose by 25%.
Kui hemoglobiinisisaldus suureneb ühe kuu kohta rohkem kui 2 g/dl (1,25 mmol/l) või kui püsiv hemoglobiinisisaldus on üle 12 g/dl (7,5 mmol/l), vähendage Abseamedi annust 25% võrra.
Only take one dose of Abseamed from each syringe.
Võtke igast süstlist ainult üks Abseamedi annus.
Patients should be monitored closely to ensure that the lowest approved dose of Abseamed is used to provide adequate control of anaemia and of the symptoms of anaemia.
Patsiente tuleb hoolikalt jälgida veendumaks, et neil esineva aneemia ja aneemia sümptomite adekvaatseks raviks kasutatakse madalaimat vajalikku Abseamedi annust.
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL
Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis Iga ml lahust sisaldab 40 000 RÜ alfaepoetiini*, mis vastab 336,0 mikrogrammile/ml.
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each mL of solution contains 40,000 IU of epoetin alfa* corresponding to 336.0 micrograms per mL
Abseamed 30 000 RÜ/0,75 ml süstelahus süstlis Iga ml lahust sisaldab 40 000 RÜ alfaepoetiini*, mis vastab 336,0 mikrogrammile/ml.
Abseamed is presented as a clear, colourless solution for injection in a pre-filled syringe.
Abseamed on selge, värvitu süstelahus süstlis.
Abseamed should be administered in order to increase haemoglobin to not greater than 12 g/dL (7.5 mmol/L).
Abseamedi manustamise eesmärgiks on saavutada hemoglobiinisisaldus, mis ei ületa 12 g/dl (7,5 mmol/l).
INFORMATION IN BRAILLE Abseamed 8,000 IU/0.8 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 8000 RÜ/0,8 ml
INFORMATION IN BRAILLE Abseamed 40,000 IU/1 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 40 000 RÜ/1 ml
INFORMATION IN BRAILLE Abseamed 9,000 IU/0.9 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 9000 RÜ/0,9 ml
• Abseamed is given by injection under the skin.
• Abseamedi manustatakse nahaaluse süstena.
INFORMATION IN BRAILLE Abseamed 7,000 IU/0.7 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 7000 RÜ/0,7 ml
INFORMATION IN BRAILLE Abseamed 30,000 IU/0.75 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 30 000 RÜ/0,75 ml
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Each syringe contains 0.75 mL of solution for injection.
Abseamed 30 000 RÜ/0,75 ml süstelahus süstlis Üks süstel sisaldab 0,75 ml lahust.
INFORMATION IN BRAILLE Abseamed 6,000 IU/0.6 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 6000 RÜ/0,6 ml
Abseamed should be administered to patients with anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)).
Aneemiaga patsientidele (nt hemoglobiini kontsentratsioon ≤ 10 g/dl ehk 6,2 mmol/l) tuleb manustada
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe Each syringe contains 0.8 mL of solution for injection.
Abseamed 8000 RÜ/0,8 ml süstelahus süstlis Üks süstel sisaldab 0,8 ml lahust.
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe Each syringe contains 0.9 mL of solution for injection.
Abseamed 9000 RÜ/0,9 ml süstelahus süstlis Üks süstel sisaldab 0,9 ml lahust.
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe Each syringe contains 0.4 mL of solution for injection.
Abseamed 4000 RÜ/0,4 ml süstelahus süstlis Üks süstel sisaldab 0,4 ml lahust.
INFORMATION IN BRAILLE Abseamed 5,000 IU/0.5 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 5000 RÜ/0,5 ml
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe Each syringe contains 0.6 mL of solution for injection.
Abseamed 6000 RÜ/0,6 ml süstelahus süstlis Üks süstel sisaldab 0,6 ml lahust.
INFORMATION IN BRAILLE Abseamed 4,000 IU/0.4 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 4000 RÜ/0,4 ml
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe EU/1/07/412/013
Abseamed 8000 RÜ/0,8 ml süstelahus süstlis EU/1/07/412/013
Abseamed is one of a group of products that stimulate the production of red blood cells like the human protein erythropoietin does.
Olge teiste vere punaliblede produktsiooni stimuleerivate toodetega eriti ettevaatlik Abseamed kuulub ravimiterühma, mis stimuleerivad vere punaliblede produktsiooni sarnaselt inimvalgu erütropoetiinile.
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe Each syringe contains 0.7 mL of solution for injection.
Abseamed 7000 RÜ/0,7 ml süstelahus süstlis Üks süstel sisaldab 0,7 ml lahust.
INFORMATION IN BRAILLE Abseamed 20,000 IU/0.5 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 20 000 RÜ/0,5 ml
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/009
Abseamed 5000 RÜ/0,5 ml süstelahus süstlis EU/1/07/412/009
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 9,000 IU/0.9 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 9000 RÜ/0,9 ml süstevedelik Alfaepoetiin i.v./s.c.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 30,000 IU/0.75 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 30 000 RÜ/0,75 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe EU/1/07/412/019
Abseamed 9000 RÜ/0,9 ml süstelahus süstlis EU/1/07/412/019
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe EU/1/07/412/023
Abseamed 30 000 RÜ/0,75 ml süstelahus süstlis EU/1/07/412/023
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe EU/1/07/412/011
Abseamed 6000 RÜ/0,6 ml süstelahus süstlis EU/1/07/412/011
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe Each syringe contains 0.3 mL of solution for injection.
Abseamed 3000 RÜ/0,3 ml süstelahus süstlis Üks süstel sisaldab 0,3 ml lahust.
INFORMATION IN BRAILLE Abseamed 1,000 IU/0.5 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 1000 RÜ/0,5 ml
INFORMATION IN BRAILLE Abseamed 3,000 IU/0.3 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 3000 RÜ/0,3 ml
INFORMATION IN BRAILLE Abseamed 10,000 IU/1 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 10 000 RÜ/1 ml
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Abseamed 40 000 RÜ/1 ml süstelahus süstlis Üks süstel sisaldab 1 ml lahust.
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis Üks süstel sisaldab 0,5 ml lahust.
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/025
Abseamed 40 000 RÜ/1 ml süstelahus süstlis EU/1/07/412/025
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 6,000 IU/0.6 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 6000 RÜ/0,6 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe EU/1/07/412/007
Abseamed 4000 RÜ/0,4 ml süstelahus süstlis EU/1/07/412/007
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 8,000 IU/0.8 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 8000 RÜ/0,8 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 8,000 IU/0.8 mL solution for injection in a pre-filled syringe
Abseamed 8000 RÜ/0,8 ml süstelahus süstlis Alfaepoetiin
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 4,000 IU/0.4 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 4000 RÜ/0,4 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/021
Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis EU/1/07/412/021
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Abseamed 5000 RÜ/0,5 ml süstelahus süstlis Üks süstel sisaldab 0,5 ml lahust.
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe EU/1/07/412/017
Abseamed 7000 RÜ/0,7 ml süstelahus süstlis EU/1/07/412/017
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe EU/1/07/412/005
Abseamed 3000 RÜ/0,3 ml süstelahus süstlis EU/1/07/412/005
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Abseamed 10 000 RÜ/1 ml süstelahus süstlis Üks süstel sisaldab 1 ml lahust.
INFORMATION IN BRAILLE Abseamed 2,000 IU/1 mL
TEAVE BRAILLE' KIRJAS (PUNKTKIRJAS) Abseamed 2000 RÜ/1 ml
Do not shake Abseamed syringes.
Abseamedi süstleid ei tohi loksutada.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 5,000 IU/0.5 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 5000 RÜ/0,5 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 40,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 40 000 RÜ/1 ml süstelahus süstlis Alfaepoetiin
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe Each syringe contains 0.5 mL of solution for injection.
Abseamed 1000 RÜ/0,5 ml süstelahus süstlis Üks süstel sisaldab 0,5 ml lahust.
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/015
Abseamed 10 000 RÜ/1 ml süstelahus süstlis EU/1/07/412/015
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 3,000 IU/0.3 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 3000 RÜ/0,3 ml süstevedelik Alfaepoetiin i.v./s.c.
What is in this leaflet What Abseamed is and what it is used for What you need to know before you use Abseamed How to use Abseamed Possible side effects How to store Abseamed Contents of the pack and other information What Abseamed is and what it is used for Abseamed contains the active substance epoetin alfa, a protein that stimulates the bone marrow to produce more red blood cells which carry haemoglobin (a substance that transports oxygen).
Mis ravim on Abseamed ja milleks seda kasutatakse Mida on vaja teada enne Abseamedi kasutamist Kuidas Abseamedi kasutada Võimalikud kõrvaltoimed
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe EU/1/07/412/003
Abseamed 2000 RÜ/1 ml süstelahus süstlis EU/1/07/412/003
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 1,000 IU/0.5 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 1000 RÜ/0,5 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 6,000 IU/0.6 mL solution for injection in a pre-filled syringe
Abseamed 6000 RÜ/0,6 ml süstelahus süstlis
Abseamed 9,000 IU/0.9 mL solution for injection in a pre-filled syringe
Abseamed 9000 RÜ/0,9 ml süstelahus süstlis
Abseamed 30,000 IU/0.75 mL solution for injection in a pre-filled syringe Epoetin alfa
Abseamed 1000 RÜ/0,5 ml süstelahus süstlis Alfaepoetiin
Abseamed 4,000 IU/0.4 mL solution for injection in a pre-filled syringe
Abseamed 4000 RÜ/0,4 ml süstelahus süstlis
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each syringe contains 1 mL of solution for injection.
Abseamed 2000 RÜ/1 ml süstelahus süstlis Üks süstel sisaldab 1 ml lahust.
Abseamed should be administered to patients with symptomatic anaemia (e.g. haemoglobin concentration ≤ 10 g/dL (6.2 mmol/L)).
Abseamedi tuleb manustada sümptomaatilise aneemiaga (nt hematoglobiinisisaldus ≤ 10 g/dl
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 40,000 IU/1 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 40 000 RÜ/1 ml süstevedelik Alfaepoetiin i.v./s.c.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 20,000 IU/0.5 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 20 000 RÜ/0,5 ml süstevedelik Alfaepoetiin i.v./s.c.
NAME OF THE MEDICINAL PRODUCT AND ROUTE(S) OF ADMINISTRATION Abseamed 10,000 IU/1 mL injection
RAVIMPREPARAADI NIMETUS JA MANUSTAMISTEE(D) Abseamed 10 000 RÜ/1 ml süstevedelik Alfaepoetiin i.v./s.c.
Abseamed 3,000 IU/0.3 mL solution for injection in a pre-filled syringe
Abseamed 3000 RÜ/0,3 ml süstelahus süstlis
Abseamed 20,000 IU/0.5 mL solution for injection in a pre-filled syringe
Abseamed 20 000 RÜ/0,5 ml süstelahus süstlis
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe EU/1/07/412/001
Abseamed 1000 RÜ/0,5 ml süstelahus süstlis EU/1/07/412/001
Talk to your doctor, pharmacist or nurse before using Abseamed.
Enne Abseamedi kasutamist pidage nõu oma arsti, apteekri või meditsiiniõega.
Abseamed 5,000 IU/0.5 mL solution for injection in a pre-filled syringe
Abseamed 5000 RÜ/0,5 ml süstelahus süstlis
Abseamed 7,000 IU/0.7 mL solution for injection in a pre-filled syringe
Abseamed 7000 RÜ/0,7 ml süstelahus süstlis
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 2000 RÜ/1 ml süstelahus süstlis
Take special care with Abseamed:
Eriline ettevaatus on vajalik ravimiga Abseamed
Abseamed 2,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 2,000 IU of epoetin alfa* corresponding to 16.8 micrograms per mL
Iga ml lahust sisaldab 2000 RÜ alfaepoetiini*, mis vastab 16,8 mikrogrammile/ml.
Abseamed 1,000 IU/0.5 mL solution for injection in a pre-filled syringe
Abseamed 1000 RÜ/0,5 ml süstelahus süstlis
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe
Abseamed 10 000 RÜ/1 ml süstelahus süstlis
Abseamed 10,000 IU/1 mL solution for injection in a pre-filled syringe Each mL of solution contains 10,000 IU of epoetin alfa* corresponding to 84.0 micrograms per mL
Iga ml lahust sisaldab 10 000 RÜ alfaepoetiini*, mis vastab 84,0 mikrogrammile/ml.
The patients were between 22 months and 72 years old.
Patsiendid olid vanuses 22 kuud kuni 72 aastat.
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu/ema/.
Täpne teave selle ravimi kohta on Euroopa Ravimiameti kodulehel: http://www.ema.europa.eu/ema/.
Lung damage may occur years after treatment.
Kopsukahjustused võivad ilmneda aastaid pärast ravi.
It is usually given at least every 6 weeks.
Tavaliselt antakse seda vähemalt iga 6 nädala tagant.
May cause birth defects.
Võib põhjustada sünnidefekte.
The duration of the treatment is determined by the doctor and may vary for each patient.
Ravi kestuse määrab arst ja see võib iga patsiendi puhul erineda.
Other medicines and Carmustine Obvius
Muud ravimid ja Carmustine Obvius
These may be signs of a severe allergic reaction.
Need võivad olla raske allergilise reaktsiooni nähud.
Store and transport refrigerated (2°C - 8°C).
Hoida ja transportida külmas (2 °C kuni 8 °C).
A specialized antidote is not available.
Spetsiaalne vastumürk ei ole kättesaadav.
Carmustine Obvius may cause the following side effects:
Carmustine Obvius võib põhjustada järgmisi kõrvaltoimeid:
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 10.
ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV 10.
Your doctor will talk to you about the possibility of lung damage and allergic reactions and their symptoms.
Arst räägib teiega kopsukahjustuste ja allergiliste reaktsioonide võimalikkusest ja nende sümptomitest.
Pulmonary toxicity has been observed in up to 30% of patients.
Pulmonaalset toksilisust on täheldatud kuni 30%-l patsientidest.
Compatibility/Incompatibility with containers
Sobimatus/kokkusobimatus mahutitega
As a doctor or nurse will be giving you this medicine, it is unlikely that you will receive an incorrect dose.
Kuna ravimit annab teile arst või meditsiiniõde, on ebatõenäoline, et saate seda vales annuses.
Two of these 8 fatalities occurred within the first 3 years of treatment and 6 of them occurred 8-13 years after treatment.
Kaks 8 surmajuhtumist esines esimese 3 raviaasta jooksul ja 6 esines 8...13 aastat pärast ravi.
A risk to the newborn/infant cannot be excluded.
Riski vastsündinule/imikule ei saa välistada.
Therefore this medicine should not normally be administered to pregnant women.
Seega tavaliselt ei tohi ravimit manustada rasedatele naistele.
Reconstitution and further dilutions should be carried out under aseptic conditions.
Manustamiskõlblikuks muutmine ja täiendavad lahjendused tuleb teha aseptilistes tingimustes.
What Carmustine Obvius is and what it is used for
Mis on Carmustine Obvius ja milleks seda kasutatakse
Carmustine Obvius should not be used during pregnancy because it may harm your unborn baby.
Carmustine Obviust ei tohi kasutada raseduse ajal, kuna see võib kahjustada sündimata last.
This medicine may cause severe (possibly fatal) lung damage.
ravim võib põhjustada raskeid (potentsiaalselt surmaga lõppevaid) kopsukahjustusi.
The median age of patients who died on treatment was 2.5 years (1-12 years), the median age of long-term survivors on treatment was 10 years (5-16 years).
Ravil olles surnud patsientide mediaanvanus oli 2,5 aastat (1...12 aastat); ravil olnud pikaajaliste ellujäänute mediaanvanus oli 10 aastat (5...16 aastat).
Doses will be adjusted according to how you respond to the treatment.
Annuseid reguleeritakse vastavalt sellele, kuidas ravile reageerite.
Carmustine Obvius should not be used in children and adolescents due to high risk of pulmonary toxicity.
Carmustine Obviust ei tohi kasutada lastel ja noorukitel pulmonaalse toksilisuse kõrge riski tõttu.
Safe use in pregnancy has not been established and therefore the benefit must be carefully weighed against the risk of toxicity.
Kasutamise ohutust raseduse ajal ei ole tõendatud ja seega tuleb kasulikkuse vs toksilisuse riski hoolikalt kaaluda.